orametrix acquisit bring addit orthodont capabl clear align
back announc acquisit orametrix provid
technolog solut orthodont care trim ep estim
acquisit bring dentspli comprehens orthodont offer
includ full arch clear align solut end-to-end digit workflow
small transact orametrix mil annual revenu vs xray
project rev bln profit howev dentspli make
increment invest busi expect dilut earn
roughli base discuss management
take step high growth market acquisit orametrix
bring enhanc capabl orthodont market particularli within
clear align space posit view tri posit
comprehens orthodont solut compani thu still offer recommend
metal bracket-and-wir brace addit clear align market align
technolog algn/overweight remain dedic clear align uptak
invisalign franchis recal receiv approv clear align jan
orametrix receiv approv sureclear clear align jan
although product launch yet xray/orametrix may track
introduc clear align product aao annual session tradeshow take place
may alreadi bake competit global market model
trim ep estim pt meantim still deal inventori
de-stock issu distributor trim ep estim
conserv push core
product sale later off-set dilut orametrix net
effect trim ep pt
reduc price-to-earnings reduc estim
quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight equal weight
compani continu re-ori manag
reshuffl continu de-stock amongst
channel partner keep lid growth
upsid case see multipl expans sale
begin improv margin expans plan set
boost ep pe would go lead price
downsid case see sale channel clear
revenu essenti grow in-lin prior year
minim margin expans would lead
multipl contract price
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
